ALZHEIMER'S ASSOCIATION STATEMENT ON GANTENERUMAB PHASE 3 TOPLINE DATA RELEASE
Retrieved on:
Monday, November 14, 2022
Cloud, Food and Drug Administration, Statute Law Revision (Substituted Enactments) Act 1876, Dementia, Alzheimer's Association, TrialMatch, Research, Genentech, Association, Safety, FDA, Volunteering, Clinical trial, Roche, Hope, Caregiver, Adaptive clinical trial, Multimedia, Learning, Skin, Gantenerumab, NIH, AIM, Food, Disease, Medical imaging, Pharmaceutical industry, Residential care, Alzheimer's disease, Neuroscience
CHICAGO, Nov. 14, 2022 /PRNewswire/ -- The Alzheimer's Association is disappointed by the topline Phase 3 data reported today by Genentech and Roche from the GRADUATE Phase 3 global clinical trials of gantenerumab.
Key Points:
- CHICAGO, Nov. 14, 2022 /PRNewswire/ -- The Alzheimer's Association is disappointed by the topline Phase 3 data reported today by Genentech and Roche from the GRADUATE Phase 3 global clinical trials of gantenerumab.
- These results, along with the positive reported data for lecanemab and FDA-approved aducanumab, are valuable for clinicians and researchers.
- We look forward to learning more about the GRADUATE trials at the Clinical Trials on Alzheimer's Disease (CTAD) meeting later this month.
- The Alzheimer's Association and the Alzheimer's Impact Movement (AIM) support the bipartisan Equity in Neuroscience and Alzheimer's Clinical Trials (ENACT) Act (S. 1548 / H.R.